Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.Most Read from ...
Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback